Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Pancreatic Cancer, Resected
Interventions
BIOLOGICAL

TG01

"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"

BIOLOGICAL

TG01

"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"

Trial Locations (5)

28050

Centro Integral Oncologico Clara Campal / Hospital HM Universitario Sanchinarro, Madrid

Unknown

Oslo University Hospital HF the Norwegian Radium Hospital, Oslo

B15 2TH

Queen Elizabeth University Hospital / Edgaston /, Birmingham

L69 3GA

University of Liverpool / Molecular and Clinical Cancer Medicine, Liverpool

M20 43 X

University of Manchester / The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Targovax ASA

INDUSTRY

NCT02261714 - Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer | Biotech Hunter | Biotech Hunter